Trial Profile
An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs CYAD 01 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Adverse reactions; Therapeutic Use
- Acronyms SHRINK
- Sponsors Celyad Oncology
- 02 Oct 2019 According to a Celyad media release, data will be presented at the 2019 SITC Annual Meeting.
- 07 May 2019 Planned number of patients changed from 39 to 36.
- 07 May 2019 Status changed from recruiting to active, no longer recruiting.